The Global Antibiotic Research & Development Partnership (GARDP) accelerates the development and access of treatments for drug-resistant infections. Together with private, public and non-profit partners, GARDP works to preserve the power of antibiotics for generations to come.
Latest news
Antibiotic resistance can affect anyone, anywhere
Antibiotic resistance occurs when bacteria change over time and no longer respond to treatment. Millions of people suffer due to antibiotic resistance every year, and nearly 1.3 million people die.
A global crisis of antibiotic resistance
Antibiotic resistance has been identified as one of the top 10 global health threats by the World Health Organization.
Antibiotic resistance is spreading all over the world as a pandemic of drug-resistant infections.
Low- and middle-income countries, and certain population groups like children and the elderly, are hit hardest.
If left unchecked, antibiotic resistance may make it too risky to carry out routine surgeries and other modern medical interventions.
GARDP is acting now to counter drug resistance and save lives
by 2025
GARDP’s “5 by 25” initiative aims to deliver five new treatments by 2025 for bacterial infections that pose the greatest threat to human health.
GARDP’s agreements with pharmaceutical and biotech companies have the potential to slash delays in access to antibiotics from decades to years.
GARDP works with governments, the pharmaceutical and biotech industry, academia, and members from civil society around the world.
